H.C. Wainwright initiated coverage of BioLife Solutions with a Buy rating and $29 price target. BioLife is a pure-play supplier of tools and services for cell and gene therapies, the analyst tells investors in a research note. The firm says BioLife is a leading supplier of cell processing tools and biostorage services for cell and gene therapy and broader biopharma markets. It says the divestiture of the freezer business improves the company’s operational efficiency.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLFS:
- BioLife Solutions management to meet with Stephens
- BioLife Solutions price target raised to $30 from $23 at Craig-Hallum
- BioLife Solutions price target raised to $28 from $26 at Northland
- BioLife Solutions raises 2024 revenue view to $99.0M-$101.0M from $95M-$100M
- BioLife Solutions reports Q2 cont-op EPS (16c), consensus (14c)